Seattle biotechnology company Atossa Genetics pulled its only product from the market late Friday, triggering a 50 percent plunge in its stock in after-hours trading. Atossa said it has begun “a voluntary recall” of its ForeCYTE Breast Health Test and the associated collection device, a pump that extracts fluid from the nipple of a nonlactating woman for “detection of precancerous changes that could lead to breast cancer.”
Help employers find you! Check out all the jobs and post your resume.
